Table 4 Cumulative survival parameter estimates with all patients with severe sepsis
Drotrecogin alfa | |||
|---|---|---|---|
Cumulative survival | PROWESS | ADDRESS | Point estimate Pooled results (± SD) |
28-day | 75.3% [13] | 81.5% [14] | 79.4% (± 1.06) |
Hospital discharge | 70.3% [8] | 79.4% [14] | 76.4% (± 1.11) |
3-month | 66.1% [8] | NA | 66.1% (± 1.86) |
6-month | 62.2% [8] | NA | 62.2% (± 1.97) |
12-month | 58.9% [8] | NA | 58.9% (± 2.05) |
30-month | 52.6% [8] | NA | 52.6%(± 2.10) |
Placebo | |||
Cumulative survival | PROWESS | ADDRESS | Pooled results (± SD) |
28-day | 69.2% [13] | 83% [14] | 78.8% (± 1.04) |
Hospital discharge | 65.1% [8] | 79.5% [14] | 74.95% (± 1.12) |
3-month | 62.4% [8] | NA | 62.4% (± 1.93) |
6-month | 60.3% [8] | NA | 60.3% (± 1.98) |
12-month | 57.2% [8] | NA | 57.2% (± 2.06) |
30-month | 49.3% [8] | NA | 49.3% (± 2.10) |